Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
Novavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.Build your future with us
Join other passionately curious people who are bringing innovative vaccines to the world
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus (SARS-CoV-2)
Breathing airborne virus-containing droplets dispersed during coughing, sneezing, or speaking among people in close contact; poorly ventilated or crowded settings; hand contact with contaminated surfaces spread to eyes, nose, or mouth by touching.
- As of January 2022, there have been approximately 300 million confirmed cases of COVID-19 globally. Of those, it is estimated that almost 5.5 million have resulted in death due to COVID-19
- May affect people of any age group; higher risk in elderly and people with chronic conditions (hypertension, heart/lung disease, diabetes, obesity, cancer)
As of January 2022, approximately 300 million people worldwide have been infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).1
What characterizes SARS-CoV-2?
Coronaviruses are characterized by their distinctive spike-shaped proteins that cover the surface of the virus; before the SARS outbreak in 2002 and the MERS outbreak in 2012, they were only known for causing typical cold-like symptoms.9,10
As we have seen with this most recent pandemic, coronaviruses can mutate, resulting in new variant virus strains, which have the potential to cause more severe respiratory disease and to spread more rapidly through the population, causing death and disability and disrupting economies.4,7,10 People of all ages can be infected with SARS-CoV-2, but older people are especially vulnerable, in particular those with underlying respiratory diseases and comorbidities.11,12
Vaccines provide protection
Apart from supportive care, there is only one drug approved, an antiviral (remdesivir), which can be used as a medical treatment for people with COVID-19, and an FDA emergency use-authorized nonvaccine antibody combination (casirivimab and imdevimab) to prevent infection.13,14 Accordingly, development of effective and safe vaccines that provide broad immunization against susceptible strains, as well as new variants, is considered the best approach in helping to protect people against the spread of this disease.15 To this end, multiple vaccines and access programs are being set up to help mitigate the impact of COVID-19 around the world.
- World Health Organization Covid-19 Dashboard. https://covid19.who.int [Accessed 27 Aug 2021].
- Centers for Disease Control and Prevention (CDC). Scientific Brief: SARS-CoV-2 Transmission. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html [Accessed 27 Aug 2021].
- Centers for Disease Control and Prevention (CDC). People with Certain Medical Conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [Accessed 27 Aug 2021].
- Liu Y-C, et al. COVID-19: the first documented coronavirus pandemic in history. Biomed J. 2020;43:328–333.
- Centers for Disease Control and Prevention (CDC). 1918 Pandemic (H1N1 virus). https://www.cdc.gov/flu/pandemic-resources/1918-pandemic-h1n1.html [Accessed 27 Aug 2021].
- Chang L, et al. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34:75–80.
- Wertheim JO, et al. A case for the ancient origin of coronaviruses. J Virol. 2013;87(12):7039–7045.
- Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J. 2005;24:S223–S227.
- Fung S, Liu D-X. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529–557.
- de Wilde AH, et al. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42.
- Perrotta F, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res. 2020;1–10 [epub ahead of print].
- Mueller AL, et al. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020;12(10):9959–9981.
- United States Food & Drug Administration (FDA). FDA News Release: FDA Approved First Treatment for COVID-19. 22 October 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 [Accessed 27 Aug 2021].
- Pharmaceutical Technology. FDA grants EUA for Regeneron’s antibody cocktail to prevent Covid-19. https://www.pharmaceutical-technology.com/news/fda-eua-regeneron-antibody-cocktail/ [Accessed 27 Aug 2021].
- Xantus GZ, et al. How to best handle vaccine decliners: scientific facts and psychological approach. Postgrad Med J. 2021;139835 [epub ahead of print].
COVID-19 Vaccine news
Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over
Novavax today announced the submission of a request to the European Medicines Agency to expand the conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the...
Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan
Novavax today announced the submission of a request for emergency use authorization to Taiwan’s Food and Drug Administration for its COVID-19 vaccine, NVX-CoV2373, for active immunization...
Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years
Novavax today announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, to expand the...